Does Gleason pattern 5 on prostate biopsy specimens accurately predict treatment outcomes in patients with prostate cancer?
McDougal
W Scott
WS
Department of Urology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
D018931:Antineoplastic Agents, Hormonal; D001706:Biopsy; D001859:Bone Neoplasms / Q000556:secondary; D001918:Brachytherapy / Q000379:methods; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D010165:Palladium / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D011868:Radioisotopes; D010165:Palladium; D017430:Prostate-Specific Antigen